Abstract:Regulatory T cells (Tregs) adoptive immunotherapy is emerging as a viable treatment option for both autoimmune and alloimmune diseases. However, numerous challenges remain, including limitations related to cell number, availability of target-specific cells, stability, purity, homing ability, and safety concerns. To address these challenges, cell engineering strategies have emerged as promising solutions. Indeed, it has become feasible to increase Treg numbers or enhance their stability through Foxp3 overexpression, post-translational modifications, or demethylation of the Treg-specific demethylated region (TSDR). Specificity can be engineered by the addition of chimeric antigen receptors (CARs), with new techniques designed to fine-tune specificity (tandem chimeric antigen receptors, universal chimeric antigen receptors, synNotch chimeric antigen receptors). The introduction of B-cell targeting antibody receptor (BAR) Tregs has paved the way for effective regulation of B cells and plasma cells. In addition, other constructs have emerged to enhance Tregs activation and function, such as optimized chimeric antigen receptors constructs and the use of armour proteins. Chimeric antigen receptor expression can also be better regulated to limit tonic signaling. Furthermore, various opportunities exist for enhancing the homing capabilities of CAR-Tregs to improve therapy outcomes. Many of these genetic modifications have already been explored for conventional CAR-T therapy but need to be further considered for CAR-Tregs therapies. This review highlights innovative CAR-engineering strategies that have the potential to precisely and efficiently manage immune responses in autoimmune diseases and improve transplant outcomes. As these strategies are further explored and optimized, CAR-Treg therapies may emerge as powerful tools for immune intervention.

Chimeric antigen receptor Treg therapy in transplantation

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

Unlocking the potential of Tregs: innovations in CAR technology

Overcoming barriers to widespread use of CAR‐Treg therapy in organ transplant recipients

The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology

Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection

Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges

Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress

Cell therapy in transplantation: A comprehensive review of the current applications of cell therapy in transplant patients with the focus on Tregs, CAR Tregs, and Mesenchymal stem cells

Regulatory T Cell Therapy for the Induction of Clinical Organ Transplantation Tolerance

Chimeric Antigen Receptor for Adoptive Immunotherapy of Cancer: Latest Research and Future Prospects.

Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance

Chimeric antigen receptor T-cell therapy in autoimmune diseases

Current status and perspectives of regulatory T cell-based therapy

Research Advances in Chimeric Antigen Receptor-Modified T-cell Therapy (Review)

Donor‐specific chimeric antigen receptor Tregs limit rejection in naive but not sensitized allograft recipients

Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases

Guiding regulatory T cells to the allograft

Therapy with regulatory T-cell infusion in autoimmune diseases and organ transplantation: A review of the strengths and limitations

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy